The Paclitaxel Paradox: Physicians Hold Steady Despite SWEDEPAD Setbacks
Despite trials failing to support the impact of paclitaxel-coated balloons and stents on key peripheral arterial disease endpoints, almost half of physicians do not intend to change their use patterns for paclitaxel-coated devices.
Intravascular Lithotripsy Holds Promise 2:1 Versus Absorbable Stents In PAD
Vascular surgeons and interventional radiologists, showed twice the level of enthusiasm for the innovation offered by Intravascular Lithotripsy than the next technology believed to show most promise, absorbable stents, in offering innovation in Peripheral Arterial Disease PAD treatment over the next three years.